Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province

References

• Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228–2233.
   PubMed Web of Science ®Google Scholar
• Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J (Yakhteh). 2017;19(1):1.
   PubMed Web of Science ®Google Scholar
• Kipp M, van der Star B, Vogel DY, et al. Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Scler Relat Dis. 2012;1(1):15–28.
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta. 2011;1812(2):246–251.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol. 2012;8(11):602.
   PubMed Web of Science ®Google Scholar
• Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):132–141.
   PubMed Web of Science ®Google Scholar
• Eskandarieh S, Heydarpour P, Elhami S-R, et al. Prevalence and incidence of multiple sclerosis in Tehran, Iran. Iranian J Public Health. 2017;46(5):699.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175.
   PubMedGoogle Scholar
• Niino M, Kikuchi S. Osteopontin and multiple sclerosis: an update. Clin Exp Neuroimmunol. 2011;2(2):33–40.
   Google Scholar
• Mishima R, Takeshima F, Sawai T, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol. 2007;41(2):167–172.
   PubMed Web of Science ®Google Scholar
• Masuda H, Takahashi Y, Asai S, et al. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn’s disease and diverticulitis. J Gastroenterol. 2005;40(4):409–413.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Ota K, Ikeguchi R, et al. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2013;263(1–2):148–151.
   PubMed Web of Science ®Google Scholar
• Kariya Y, Kariya Y, Saito T, et al. Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. BBA Clin. 2015;3:126–134.
   PubMedGoogle Scholar
• Husain-Krautter S, Kramer JM, Li W, et al. The osteopontin transgenic mouse is a new model for Sjögren's syndrome. Clin Immunol. 2015;157(1):30–42.
   PubMed Web of Science ®Google Scholar
• Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005;158(1–2):231–239.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Cheng W, Xi Y, et al. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis. Mol Immunol. 2018;93:20–30.
   PubMed Web of Science ®Google Scholar
• Vogt MH, ten Kate J, Drent RJ, et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010;16(4):443–449.
   PubMed Web of Science ®Google Scholar
• Wen S-R, Liu G-J, Feng R-N, et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2012;244(1–2):94–96.
   PubMed Web of Science ®Google Scholar
• Jansson M, Panoutsakopoulou V, Baker J, et al. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol. 2002;168(5):2096–2099.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 2008;181(11):7480–7488.
   PubMed Web of Science ®Google Scholar
• Shinohara ML, Kim J-H, Garcia VA, et al. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity. 2008;29(1):68–78.
   PubMed Web of Science ®Google Scholar
• Choi J-S, Park H-J, Cha J-H, et al. Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol. 2003;141(1–2):65–73.
   PubMed Web of Science ®Google Scholar
• Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294(5547):1731–1735.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Amedei A, Prisco D, D’Elios M. Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci. 2012;13(12):13438–13460.
   PubMed Web of Science ®Google Scholar
• Khaibullin T, Ivanova V, Martynova E, et al. Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. Front Immunol. 2017;8:531.
   PubMed Web of Science ®Google Scholar
• Kozovska M, Hong J, Zang Y, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53(8):1692.
   PubMed Web of Science ®Google Scholar
• Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing–remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg. 2006;108(2):124–128.
   PubMed Web of Science ®Google Scholar
• Gessani S, Conti L, Del Cornò M, et al. Type I interferons as regulators of human antigen presenting cell functions. Toxins. 2014;6(6):1696–1723.
   PubMed Web of Science ®Google Scholar
• Kasper LH, Reder AT. Immunomodulatory activity of interferon‐beta. Ann Clin Transl Neurol. 2014;1(8):622–631.
   PubMed Web of Science ®Google Scholar
• Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis. Ann Neurol. 2003;53(6):819–822.
   PubMed Web of Science ®Google Scholar
• Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest. 2008;118(5):1680–1690.
   PubMed Web of Science ®Google Scholar
• Prinz M, Schmidt H, Mildner A, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 2008;28(5):675–686.
   PubMed Web of Science ®Google Scholar
• Chen M, Chen G, Nie H, et al. Regulatory effects of IFN‐β on production of osteopontin and IL‐17 by CD4+ T Cells in MS. Eur J Immunol. 2009;39(9):2525–2536.
   PubMed Web of Science ®Google Scholar